Modulation of beta bursts in subthalamic sensorimotor circuits predicts improvement in bradykinesia.

ABSTRACT: No biomarker of Parkinson's disease exists that allows clinicians to adjust chronic therapy, either medication or deep brain stimulation, with real-time feedback. Consequently, clinicians rely on time-intensive, empirical, and subjective clinical assessments of motor behaviour and adverse events to adjust therapies. Accumulating evidence suggests that hypokinetic aspects of Parkinson's disease and their improvement with therapy are related to pathological neural activity in the beta band (beta oscillopathy) in the subthalamic nucleus. Additionally, effectiveness of deep brain stimulation may depend on modulation of the dorsolateral sensorimotor region of the subthalamic nucleus, which is the primary site of this beta oscillopathy. Despite the feasibility of utilizing this information to pr

SUBMITTER: Kehnemouyi YM 

PROVIDER: S-EPMC8240742 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature